

Resource Summary Report

Generated by ASWG on Aug 4, 2026

CTDatabase

RRID:SCR_007614

Type: Tool

Proper Citation

CTDatabase (RRID:SCR_007614)

Resource Information

URL: <http://www.cta.lncc.br/>

Proper Citation: CTDATABASE (RRID:SCR_007614)

Description: A database of information about each Cancer-Testis (CT) gene, its gene products and the immune response induced in cancer patients by these proteins. CT antigens are proteins normally expressed only in the human germ line but that are also present in a significant subset of malignant tumors. The practical importance of these proteins is that due to their restricted expression pattern they are frequently recognized by the immune system of cancer patients. Moreover, this antigenicity has raised the possibility of their being used as vaccines to actively stimulate immune responses in order to combat tumor growth. As a result worldwide research into many aspects of CT antigens is rapidly growing prompting the construction of this database as a resource for investigators involved in this area.

Synonyms: CTDATABASE

Resource Type: data or information resource, database

Keywords: data set, FASEB list

Related Condition: Cancer

Resource Name: CTDATABASE

Resource ID: SCR_007614

Alternate IDs: nif-0000-02704

Record Creation Time: 20220129T080242+0000

Record Last Update: 20260804T043336+0000

Ratings and Alerts

No rating or validation information has been found for CTDATABASE.

No alerts have been found for CTDATABASE.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 93 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Chen A, et al. (2025) Expression of Cancer-Testis Antigens MAGE-A1, MAGE-A4, NY-ESO-1 and PRAME in Bone and Soft Tissue Sarcomas: The Experience From a Single Center in China. *Cancer medicine*, 14(7), e70750.

Qiu Z, et al. (2025) Screening colorectal cancer associated autoantigens through multi-omics analysis and diagnostic performance evaluation of corresponding autoantibodies. *BMC cancer*, 25(1), 713.

Pandey K, et al. (2025) Multiple Classes of Antigen Contribute to the Antigenic Landscape of Mesothelioma. *Molecular & cellular proteomics : MCP*, 24(3), 100925.

Alip M, et al. (2025) A cancer-testis antigen signature for predicting prognosis and response to immunotherapy in acute myeloid leukemia. *Medicine*, 104(50), e46374.

Lemke S, et al. (2025) PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development. *Journal for immunotherapy of cancer*, 13(4).

Azimi P, et al. (2025) Cancer/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients. *PloS one*, 20(6), e0326054.

Verma S, et al. (2024) Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer. *Cancers*, 16(2).

Beckabir W, et al. (2024) Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. *Nature communications*, 15(1), 4448.

Yi X, et al. (2024) Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. *Cell reports methods*, 4(11), 100906.

Kortleve D, et al. (2024) TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. *Cancer discovery*, 14(12), 2450.

Meijer DM, et al. (2024) Enhanced immune responses are accompanied by increased MAGEA expression in osteosarcoma metastases. *BMJ oncology*, 3(1), e000472.

Garcia-Marquez MA, et al. (2024) Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides. *Journal for immunotherapy of cancer*, 12(4).

Jacquet E, et al. (2023) Aberrant activation of five embryonic stem cell-specific genes robustly predicts a high risk of relapse in breast cancers. *BMC genomics*, 24(1), 463.

Alrubie TM, et al. (2023) Higher Expression Levels of SSX1 and SSX2 in Patients with Colon Cancer: Regulated In Vitro by the Inhibition of Methylation and Histone Deacetylation. *Medicina (Kaunas, Lithuania)*, 59(5).

Zeng X, et al. (2023) Prediction and identification of HLA-A*0201-restricted epitopes from cancer testis antigen CT23. *Human vaccines & immunotherapeutics*, 19(3), 2293299.

Medici G, et al. (2023) A T-cell antigen atlas for meningioma: novel options for immunotherapy. *Acta neuropathologica*, 146(2), 173.

Ren S, et al. (2023) Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review). *International journal of oncology*, 62(6).

Carter JA, et al. (2023) Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis. *Journal for immunotherapy of cancer*, 11(12).

Raj SKS, et al. (2022) Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. *Cancer*, 128(17), 3254.

Paslaru L, et al. (2022) Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology. *Medicina (Kaunas, Lithuania)*, 58(12).